The treatment scheme and prognosis of patients with NENs are mainly assessed by morphology and tumor grade, which are dependent on the mitotic count or Ki-67 labeling index, but they exhibit different survival outcomes, even when the same therapy is used for the same tumor grade. The gene discussed is MKI67; the disease is neoplasm.